[go: up one dir, main page]

WO2006048209A1 - Nouveaux antagonistes de la bradykinine b1, procedes de production et d'utilisation en tant que medicaments associes, - Google Patents

Nouveaux antagonistes de la bradykinine b1, procedes de production et d'utilisation en tant que medicaments associes, Download PDF

Info

Publication number
WO2006048209A1
WO2006048209A1 PCT/EP2005/011602 EP2005011602W WO2006048209A1 WO 2006048209 A1 WO2006048209 A1 WO 2006048209A1 EP 2005011602 W EP2005011602 W EP 2005011602W WO 2006048209 A1 WO2006048209 A1 WO 2006048209A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
ethyl
dihydro
imidazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/011602
Other languages
German (de)
English (en)
Inventor
Iris Kauffmann-Hefner
Norbert Hauel
Henri Doods
Angelo Ceci
Stefan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004054053A external-priority patent/DE102004054053A1/de
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to EP05800514A priority Critical patent/EP1812405A1/fr
Priority to JP2007538344A priority patent/JP2008518889A/ja
Priority to CA002585535A priority patent/CA2585535A1/fr
Publication of WO2006048209A1 publication Critical patent/WO2006048209A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Novel bradykinin B1 antagonists processes for their preparation and their use as pharmaceuticals
  • the present invention relates to bradykinin B1 antagonists of the general formula
  • A, Ar, G, Q, R 1 and R 4 are as defined in claim 1, their enantiomers, their diastereomers, their mixtures and their salts, in particular their physiologically acceptable salts with organic or inorganic acids or bases, which have valuable properties , their preparation, the medicaments containing the pharmacologically active compounds, their preparation and their use.
  • R 1 is a phenyl, naphthyl or heteroaryl group, a phenyl-C- ⁇ . 3- alkyl or C 3-7 -cycloalkyl group,
  • R 4 is a hydrogen atom or a Ci- 6 alkyl group
  • G is the group - (CH 2 ) m -, in which m is the number 2 or 3 and in which one to three hydrogen atoms can be replaced independently of one another by C 1-3 -alkyl groups,
  • Ar is a phenylene or heteroarylene group
  • Q is the group - (CH 2 ) P -, in which p is the number 2 or 3 and in which one to three hydrogen atoms are independently of one another by Ci. 3- alkyl groups can be replaced,
  • A is a radical of the general formula (IIa) to (Mi) linked via a nitrogen atom to the sulfonyl group in formula (I)
  • R 2 is a hydrogen atom, a Ci -6 alkyl, C 2 - methyl-5 -alkenyl, C. 2 5- alkynyl-methyl, C 3-7 -cycloalkyl or a phenyl group and
  • R 3 is a hydrogen atom, a phenyl, Ci- 6 alkyl, C 2 - 5 alkenyl-methyl, C 2-5 alkynyl or C 3-7 cycloalkyl-methyl or a group -CH 2 -CF 3 , -CH 2 -CHF 2 or -CH 2 -CH 2 F,
  • heteroaryl group a monocyclic 5- or 6-membered or a bicyclic 9- or 10-membered heterocyclic, aromatic ring system which in addition to at least one carbon atom one or more heteroatoms selected from N, O and / or S includes, for example
  • Ci- 3 alkyl optionally substituted by a Ci- 3 alkyl, phenyl, amino-C 2 - 3 alkyl, ds-alkylamino-Ca-s-alkyl- or di- (Ci-C3 alkyl.) -amino-C2- 3 alkyl group, by a 4- to 7-membered cycloalkyleneimino-C 1 . 3 alkyl or phenyl-Ci -3 alkyl substituted imino group or an oxygen or sulfur atom and additionally a nitrogen atom or one containing optionally substituted by a Ci- 3 alkyl or phenyl-Ci -3 alkyl substituted imino group and two or three nitrogen atoms, or
  • a bicyclic 9-membered heteroaryl group consisting of one of the above-mentioned 5-membered heteroaryl groups condensed with one of the above-mentioned 6-membered heteroaryl groups through two adjacent carbon atoms or a carbon atom and an adjacent nitrogen atom to form a bicyclic nucleus;
  • the heteroaryl group may also be replaced by a cyclopentadienyl group or the 6-membered heteroaryl group by a phenyl ring, or
  • bicyclic 10-membered heteroaryl group consisting of a phenyl ring and one of the above-mentioned 6-membered heteroaryl groups or two of the above-mentioned 6-membered heteroaryl groups each condensed through two adjacent carbon atoms to a bicyclic group,
  • Heteroaryl groups additionally in the carbon skeleton by fluorine, chlorine; Bromo- or iodine atoms or mono-, di- or trisubstituted by Ci-3-alkyl groups and the substituents may be the same or different, and
  • heteroarylene group refers to the abovementioned mono- or bicyclic heteroaryl groups, but which are linked to the adjacent groups via two carbon atoms or one carbon atom and one nitrogen atom,
  • alkyl and alkoxy groups having more than two carbon atoms contained in the above-mentioned definitions may be straight-chain or branched, and wherein the hydrogen atoms of the methyl or ethyl groups contained in the above-mentioned definitions may be wholly or partly replaced by fluorine atoms,
  • Examples of monocyclic heteroaryl groups are the pyridyl, ⁇ / -oxypyridyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, [1, 2,3] triazinyl, [1, 3,5] triazinyl, [ 1, 2,4] triazinyl, pyrrolyl, imidazolyl, [1, 2,4] triazolyl, [1, 2,3] triazolyl, tetrazolyl, furanyl, isoxazolyl, oxazolyl, [1, 2,3] oxadiazolyl, [1, 2,4] oxadiazolyl, [1, 2,5] oxadiazolyl, [1, 3,4] oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl or [1, 2 , 4] thiadiazolyl group.
  • bicyclic heteroaryl groups are the benzimidazolyl, benzofuranyl, benzo [c] furanyl, benzo [b] thiophenyl, benzo [c] thiophenyl, benzothiazolyl, benzo [c] isothiazolyl, benzo [d] isothiazolyl, Benzooxazolyl, benzo [c] isoxazolyl, benzo [d] isoxazolyl, benzo [1, 2,5] oxadiazolyl, benzo [1, 2,5] thiadiazolyl, benzo [1,2,3] thia- diazolyl, benzo [d] [1, 2,3] triazinyl, benzo [1,2,4] triazinyl, benzotriazolyl, cinnolinyl, quinolinyl, N-oxy quinolinyl, indazolyl, purinyl, Naphthyridinyl, pteridinyl,
  • Ci -6- alkyl groups are the methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, ferf-butyl, 1-pentyl , 2-pentyl, 3-pentyl, ⁇ eo-pentyl, 1-hexyl, 2-hexyl or 3-hexyl.
  • a second embodiment of the present invention consists in the compounds of the above general formula (I) in which
  • R 1 is a phenyl, naphthyl, or heteroaryl group, a phenyl-Ci -3 alkyl or C 3-6 cycloalkyl group
  • R 4 is a hydrogen atom or a Ci -4 alkyl group
  • G is the group - (CH 2) m - in which m is the number 2 or 3 and in which one to three hydrogen atoms independently replaced by Ci -3 alkyl groups, for example methyl groups may be replaced,
  • Ar is a phenylene group
  • Q is the group - (CH 2) P -, where p is the number 2 or 3 and in which one to three hydrogen atoms independently replaced by Ci -3 alkyl groups, for example methyl groups may be replaced,
  • A is a radical linked via a nitrogen atom to the sulfonyl group in formula (I), of the general formula (IIa), (IIb), (Hc), (Hd), (He), (Hf), (Hg), (Mh) or (Hi) 1
  • n is the number 2 or 3
  • R 2 is a hydrogen atom, a Ci -4 alkyl, C 2 - 5 alkenyl-methyl, C 3 - 6 cycloalkyl or a phenyl group and
  • R 3 is a hydrogen atom, a C- ⁇ - 4 alkyl, C 2 - 5 alkenyl-methyl, or C 3-6 cycloalkyl group or a Ci. 3- alkyl group in which each methyl group may be substituted by up to three and each methylene group may be substituted by up to two fluorine atoms,
  • naphthyl groups contained in the above-mentioned definitions by fluorine, chlorine or bromine atoms, by Ci. 3- alkyl, amino or di (C 1-3 alkyl) - amino groups may be mono- or disubstituted and the substituents may be the same or different,
  • heteroaryl group is to be understood as meaning a monocyclic 5- or 6-membered or a bicyclic 9- or 10-membered heterocyclic, aromatic ring system, for example
  • an imino group optionally substituted by a C 1-3 -alkyl, phenyl or phenyl-C 1-3 -alkyl group, an oxygen or sulfur atom or
  • Ci. 3 -alkyl or phenyl group an optionally by a Ci. 3 -alkyl or phenyl group, by a 5- to 7-membered cycloalkyleneimino-Ci-s-alkyl or a phenyl-Ci- 3 -alkyl group-substituted imino group or an oxygen or sulfur atom and additionally a nitrogen atom or optionally substituted by a Ci- 3 alkyl or phenyl-Ci. 3 -alkyl group substituted imino group and additionally contains two nitrogen atoms, or
  • a bicyclic 9-membered heteroaryl group consisting of one of the aforementioned 5-membered heteroaryl groups fused to one of the aforementioned 6-membered heteroaryl groups via two adjacent carbon atoms or a carbon and an adjacent nitrogen atom to form a bicyclic compound; also be replaced by a cyclopentadienyl or the 6-membered heteroaryl group by a phenyl ring, or heteroaryl group may also be replaced by a phenyl ring
  • bicyclic 10-membered heteroaryl group consisting of a phenyl ring and one of the above-mentioned 6-membered heteroaryl groups or two of the above-mentioned 6-membered heteroaryl groups each condensed through two adjacent carbon atoms to a bicyclic group,
  • heteroarylene group refers to the abovementioned mono- or bicyclic heteroaryl groups, but which are linked to the adjacent groups via two carbon atoms or one carbon atom and one nitrogen atom,
  • alkyl and alkoxy groups having more than two carbon atoms contained in the above-mentioned definitions, unless otherwise mentioned, may be straight-chain or branched, and
  • a third embodiment of the present invention consists in the compounds of the above general formula (I) in which
  • R 1 is optionally substituted by fluorine, chlorine or bromine atoms, nitro, cyano, Ci- 3 -AlkyIsulfonyl-, Ci- 5 alkyl, trifluoromethyl, hydroxy, Ci -5 alkyloxy, trifluoromethoxy, phenyloxy , Morpholin-4-ylsulfonyl, phenyl,
  • a C 3 - 6 cycloalkyl for example the cyclopropyl
  • R 4 is a hydrogen atom or a methyl group
  • G is the group - (CH2) m -, in which m is the number 2 or 3 or the group - (CH 2 ) m -, in which m is the number 2 or 3 and in which one, two or three hydrogen atoms are independently replaced by methyl or ethyl groups,
  • Ar is a phenylene group
  • Q is the group - (CH 2 ) P -, where p is the number 2, or
  • A is a radical of the general formula (IIa), (IIb), (IIc), (Hd), (Me), (Hf), (IIg) linked via the position marked * with the sulfonyl group in formula (I), (Hh) or (Hi),
  • n is the number 2 or 3
  • R 2 is a hydrogen atom, a C 1-3 alkyl, cyclopropyl or a phenyl group and
  • R 3 is a hydrogen atom, a cyclopropyl group, a linear or branched Ci -3 alkyl group, F 3 C-CH 2 -, F 2 CH-CH 2 - or H 2 FC-CH 2 group,
  • a fourth embodiment of the present invention consists in the compounds of the above general formula (I) in which R 1 is an isopropyl, cyclopropyl, phenyl, phenylmethyl, 2,4-dichlorophenylmethyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl -, 3-fluorophenyl, 4-fluorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 3,5 - dichlorophenyl, 2,4,5-trichlorophenyl, 3,4-difluorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-4-cyanophenyl, 5-fluoro-2-methylphenyl, 2-ch
  • R 4 is a hydrogen atom or a methyl group
  • G is the group - (CH 2 ) m-, where m is 2 or 3 or the group - (CH 2 ) m -, in which m is the number 2 or 3 and in which one or two hydrogen atoms are independently replaced by methyl groups,
  • Ar is an -3 alkyl, trifluoromethyl, Ci -3 alkyloxy or trifluoromethoxy groups independently of one another mono- or disubstituted optionally substituted by fluorine, chlorine or bromine atoms, cyano, Ci, however, preferably unsubstituted phenylene,
  • Q is the group - (CH 2 ) P -, where p is the number 2, or
  • A is a radical of the general formula (IIa), (IIb), (Mc) 1 (Hd), (Me), (Hf), (Mg) 1 linked via the position marked * with the sulfonyl group in formula (I) (Hh) or (Hi), but preferably a radical of the formula (IIa), (IIb), (Hc), (Ile), (Hf), (Hg), (Hh) or (Hi),
  • n is the number 2 or 3
  • R 2 is a hydrogen atom, a methyl, ethyl, n-propyl, i-propyl, cyclopropyl or phenyl group and
  • R 3 represents a hydrogen atom, a methyl, ethyl, n-propyl, i-propyl, 2-monofluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl or cyclopropyl group,
  • phenyl groups or the phenyl groups contained in the abovementioned radicals are independently of one another fluorine, chlorine or bromine atoms, Cyano, Ci -3 alkyl, trifluoromethyl, mono- 3 d- alkyloxy or trifluoromethoxy, or may be di-substituted, but preferably unsubstituted,
  • R 1 is a phenyl or heteroaryl group
  • R 4 is a hydrogen atom or a C 1-6 -alkyl group
  • n 2 or 3
  • Ar is a phenylene or heteroarylene group
  • A is a radical of the general formula
  • n is the number 2 or 3
  • o the number 1, 2 or 3
  • R 2 is a hydrogen atom, a d- ⁇ -alkyl, C 2 - 3 alkenyl, C 2 - 3 alkynyl, C 3 .7-cyclo- alkyl or a phenyl group and
  • R 3 is a hydrogen atom, a Ci. 6 alkyl, C 2 . 3 alkenyl, C 2-3 alkynyl or C 3-7 cycloalkyl group,
  • heteroaryl group refers to a monocyclic 5- or 6-membered heteroaryl group, where
  • the 6-membered heteroaryl group contains one, two or three nitrogen atoms and
  • C- ⁇ -3 alkyl phenyl, amino C 2 . 3- alkyl, C 1-3 -alkyl-amino-C 2 . 3 alkyl-, di- (Ci. 3 alkyl) amino-C 2-3 alkyl-, a 4- to 7-membered alkyleneimino cyclo-Ci-3-alkyl or phenyl-C- ⁇ - 3 alkyl group substituted imino group or an oxygen or sulfur atom and additionally a nitrogen atom or
  • alkyl and alkoxy groups having more than two carbon atoms contained in the above-mentioned definitions, unless otherwise mentioned, may be straight-chain or branched,
  • the hydrogen atoms of the methyl or ethyl groups contained in the above-mentioned definitions may be wholly or partly replaced by fluorine atoms
  • the phenyl groups contained in the abovementioned definitions can be mono-, di- or trisubstituted by fluorine, chlorine, bromine or iodine atoms, C 1-3 -alkyl, trifluoromethyl, C 1-3 -alkyloxy or trifluoromethyloxy groups
  • a second, particularly to be mentioned embodiment of the present invention consists in the compounds of general formula (I 1 ), in which
  • R 1 is an optionally mono-, di- or trisubstituted phenyl group by chlorine atoms or methyl groups, where the substituents may be identical or different,
  • R 4 is a hydrogen atom
  • Ar is a phenylene group
  • A is a radical of the general formula
  • n is the number 2 or 3
  • R 2 is a hydrogen atom, a Ci -3 alkyl, cyclopropyl or phenyl group and
  • R 3 is a hydrogen atom or a methyl group
  • the compounds of general formula (I) are prepared by methods known in principle. The following processes have proven particularly suitable for the preparation of the compounds of general formula (I) according to the invention: (a) For the preparation of compounds of the general formula (I) in which R 1 , R 4 , G, A, Q and Ar are defined as mentioned in the introduction:
  • the reaction is preferably carried out at a temperature of 40 0 C to 150 ° C in a solvent such as tetrahydrofuran, dioxane, n-hexane, cyclohexane, benzene, toluene or xylene.
  • a solvent such as tetrahydrofuran, dioxane, n-hexane, cyclohexane, benzene, toluene or xylene.
  • the reaction is carried out with the addition of P 2 S 5 or sulfur.
  • R 1 , G, A, Q and Ar are defined as mentioned above and PG is an amine protecting group, for example the tert-butyloxycarbonyl protective group, the benzyloxycarbonyl, methoxycarbonyl or ethoxycarbonyl group, according to literature methods (see, for example: Protective Groups in Organic Chemistry, 2nd Edition, Ed .: TWGreene, PMGWuts, John Wiley &
  • the intermediates (III) and (V) can be prepared by forming a carboxylic acid amide linkage from carboxylic acid and amino moieties selected from the group consisting of (wherein in the following formulas (VIa) to (VId ) the ethylene group linked with Ar is only an example of the meanings of the group Q in formula (I))
  • Ar, R 1 , R 2 , R 3 , m, n and o are defined as mentioned above and PG is an amine protecting group, for example the fert-butyloxycarbonyl protecting group, the benzyloxycarbonyl, methoxycarbonyl or ethoxycarbonyl group.
  • the coupling is preferably carried out using methods known from peptide chemistry (see, for example, Houben-Weyl, Methods of Organic Chemistry, Vol. 15/2), for example carbodiimides, such as, for example, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or ethyl (3-dimethylaminopropyl) carbodiimide, O- (1 / - / - benzotriazol-1-yl) - ⁇ /, ⁇ / - / V, / V-tetramethyluronium hexafluorophosphate (HBTU ) or tetrafluoroborate (TBTU) or 1 H-benzotriazol-1-yl-oxytris (dimethylamino) phosphonium hexafluorophosphate (BOP).
  • DEC dicyclohexylcarbodiimide
  • DIC diisopropylcarbod
  • the reaction rate can be increased.
  • the couplings are usually between equimolar proportions of the coupling components and the coupling reagent in solvents such as dichloromethane, tetrahydrofuran, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMA), ⁇ / -methylpyrrolidone (NMP) or mixtures of these and at temperatures between -3O 0 C and +30 0 C, preferably -20 0 C and + 25 ° C performed.
  • solvents such as dichloromethane, tetrahydrofuran, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMA), ⁇ / -methylpyrrolidone (NMP) or mixtures of these and at temperatures between -3O 0 C and +30 0 C, preferably -20 0 C and + 25 ° C performed.
  • DIEA ⁇ / -Ethyldiisopropylamin
  • N - Ar - Q - X t (V
  • Ar and Q are defined as mentioned above and X represents a nucleofugic group, for example the chlorine, bromine or iodine atom, the methanesulfonyl or toluenesulfonyl group.
  • the reaction takes place under the action of a base such as, for example, potassium tert-butoxide or sodium hydride, preferably in a solvent such as dimethylformamide or dimethyl sulfoxide.
  • a base such as, for example, potassium tert-butoxide or sodium hydride
  • a solvent such as dimethylformamide or dimethyl sulfoxide.
  • R 1 , Q and Ar are defined as mentioned above and A corresponds to a radical of the abovementioned general formula (Md):
  • R 1 and R 2 are defined as mentioned above and X has the meaning of a nucleofugic group, such as the chlorine, bromine or iodine atom, the methanesulfonyl or toluenesulfonyl group.
  • the reaction takes place under the action of a base such as butyllithium or lithium diisopropylamide, preferably in a solvent such as tetrahydrofuran or in a solvent mixture of tetrahydrofuran with hexane or toluene.
  • a base such as butyllithium or lithium diisopropylamide
  • a solvent such as tetrahydrofuran or in a solvent mixture of tetrahydrofuran with hexane or toluene.
  • the compounds of the general formula (I) obtained may, provided they contain suitable basic functions, be converted, in particular for pharmaceutical applications, into their physiologically acceptable salts with inorganic or organic acids.
  • suitable acids are hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, acetic, fumaric, succinic, lactic, mandelic, malic, citric, tartaric and maleic acids.
  • novel compounds of the formula (I), if they contain carboxylic acid function, can if desired be converted into their addition salts with inorganic or organic bases, in particular for the pharmaceutical application, into their physiologically tolerable addition salts.
  • Suitable bases for this example, sodium hydroxide, potassium hydroxide, ammonia, cyclohexylamine, dicyclohexylamine, ethanolamine, diethanolamine and triethanolamine into consideration.
  • the present invention relates to racemates, provided that the compounds of the general formula (I) have only one chiral element.
  • the application also includes the individual pairs of diastereomeric antipodes or mixtures thereof which are present when more than one chiral element is present in the compounds of general formula (I) and the individual optically active enantiomers constituting the racemates mentioned.
  • Also included in the subject matter of this invention are the compounds according to the invention, including their salts, in which one or more hydrogen atoms are replaced by deuterium.
  • novel compounds of the general formula (I) and their physiologically tolerated salts have valuable pharmacological properties. they provide Bradykinin B1 antagonists.
  • CHO cells expressing the hBK1 receptor are cultured in "Dulbecco's modified medium.” From confluent cultures, the medium is removed, the cells are washed with PBS buffer, scraped and isolated by centrifugation, then the cells are homogenized in suspension , the homogenate is centrifuged and resuspended. After determining the protein content of the membrane preparation thus obtained is stored frozen at -8O 0 C.
  • the bound radioactivity is defined in the presence of 1.0 // M kallidine (DesArg10, Leu9), [3,4-prolyl-3,43H (N)].
  • concentration-binding curve is carried out by means of a computer-aided non-linear curve fitting. From the data thus obtained, the corresponding Ki value is determined for the test substance.
  • novel compounds and their physiologically acceptable salts are useful in the treatment of diseases and disease symptoms caused, at least in part, by the stimulation of bradykinin B1 receptors.
  • the compounds of the invention can be used in methods which serve to alleviate or treat pain, wherein a patient is administered a therapeutically effective amount of the compound of the invention.
  • neuropathic pain or post-operative pain are suitable for the treatment of patients with chronic pain, neuropathic pain or post-operative pain, inflammatory pain, perioperative pain, migraine, arthralgia, neuropathies, nerve injuries, diabetic neuropathy, neurodegeneration, neurotic skin diseases, stroke, hypersensitivity of the bladder, irritable bowel Respiratory diseases such as asthma or chronic obstructive pulmonary disease, irritation of the skin, eyes or mucous membranes, duodenal and gastric ulcers, gastritis or others Inflammatory diseases, pain caused by osteoarthritis, back pain, as well as pain associated with another etiology.
  • Respiratory diseases such as asthma or chronic obstructive pulmonary disease, irritation of the skin, eyes or mucous membranes, duodenal and gastric ulcers, gastritis or others
  • Inflammatory diseases pain caused by osteoarthritis, back pain, as well as pain associated with another etiology.
  • the dose required to produce an analgesic effect is advantageously 0.01 to 3 mg / kg body weight, preferably 0.1 to 1 mg / kg when given intravenously, and 0.1 to 8 mg / kg body weight, preferably 0.5 to 3 mg / kg, respectively, when given orally 1 to 3 times a day.
  • the compounds prepared according to the invention can be administered intravenously, subcutaneously, intramuscularly, intrarectally, intranasally, by inhalation, transdermally or orally, in particular aerosol formulations being suitable for inhalation.
  • they may be combined with one or more inert conventional carriers and / or diluents, e.g.
  • lactose cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerin, water / sorbitol, water / polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or their suitable mixtures be incorporated into common pharmaceutical preparations such as tablets, dragees, capsules, powders, suspensions, solutions, metered aerosols or suppositories.
  • IR, 1 H-NMR and / or mass spectra are generally present.
  • the ratios stated for the flow agents refer to Volume units of the respective solvents.
  • the indicated volume units at NH 3 refer to a concentrated solution of NH 3 in water.
  • the acid, base and salt solutions used in the workup of the reaction solutions are aqueous systems of the indicated concentrations.
  • silica gel from Millipore 35-70 ⁇ m
  • Alox E. Merck, Darmstadt, aluminum oxide 90 standardized, 63-200 ⁇ m, article no: 1.01097.9050
  • V-methyl-acetamide hydrochloride was prepared analogously to 1 i) from 0.5 g (0.97 mmol) of 2- [4- (2- ⁇ [2- (benzenesulfonylmethylamino) -acetyl] -methylamino ⁇ -ethyl) -phenyl] -4 Tert-butyl 5-dihydroimidazole-1-carboxylate and 5 ml trifluoroacetic acid in 15 ml
  • 2-yl) -phenyl] - / V-methylpropionamide was analogous to 13b) from 0.7 g (1.49 mmol) of 3- (4-cyanophenyl) - ⁇ / - ⁇ 3 - [(2,3-dichlorobenzenesulfonyl) -methylamino] - propyl ⁇ - ⁇ / -methylpropionamide, 0.1 g (3.12 mmol) of sulfur and 3 ml of ethylenediamine.
  • the crude product thus obtained was purified by column chromatography on silica gel (eluent: dichloromethane / methanol / NH 3 13: 1: 0.1 to 8: 1: 0.1). The product was then transferred to the hydrochloride with ethereal hydrochloric acid and lyophilized.
  • Example 55 3 - [(2-chloro-4-trifluoromethylbenzenesulfonyl) methylamino] - ⁇ / - ⁇ 2- [4- (4,5-dihydro-1H-imidazol-2-yl) -phenyl] -ethyl ⁇ - ⁇ / -methylpropionamide trifluoroacetate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des antagonistes de la bradykinine B1 de formule (I), dans laquelle A, Ar, G, Q, R1 et R4 sont spécifiés dans la revendication 1, leurs énantiomères, leurs diastéréomères, leurs mélanges et leurs sels, en particulier leurs sels phyiologiquement acceptables comprenant des acides ou des bases organiques ou inorganiques, lesquels présentent des propriétés précieuses. L'invention concerne également leur production, des médicaments contenant les composés pharmaceutiquement actifs, leurs production et leur utilisation.
PCT/EP2005/011602 2004-11-05 2005-10-29 Nouveaux antagonistes de la bradykinine b1, procedes de production et d'utilisation en tant que medicaments associes, Ceased WO2006048209A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05800514A EP1812405A1 (fr) 2004-11-05 2005-10-29 Nouveaux antagonistes de la bradykinine b1, procedes de production et d'utilisation en tant que medicaments associes,
JP2007538344A JP2008518889A (ja) 2004-11-05 2005-10-29 新規ブラジキニンｂ１アンタゴニスト、それらの製造方法及び薬物としてのそれらの使用
CA002585535A CA2585535A1 (fr) 2004-11-05 2005-10-29 Nouveaux antagonistes de la bradykinine b1, procedes de production et d'utilisation en tant que medicaments associes,

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004054053A DE102004054053A1 (de) 2004-11-05 2004-11-05 Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004054053.5 2004-11-05
DE102005013967A DE102005013967A1 (de) 2004-11-05 2005-03-26 Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005013967.1 2005-03-26

Publications (1)

Publication Number Publication Date
WO2006048209A1 true WO2006048209A1 (fr) 2006-05-11

Family

ID=36090377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/011602 Ceased WO2006048209A1 (fr) 2004-11-05 2005-10-29 Nouveaux antagonistes de la bradykinine b1, procedes de production et d'utilisation en tant que medicaments associes,

Country Status (6)

Country Link
US (1) US7291642B2 (fr)
EP (1) EP1812405A1 (fr)
JP (1) JP2008518889A (fr)
CA (1) CA2585535A1 (fr)
DE (1) DE102005013967A1 (fr)
WO (1) WO2006048209A1 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022945A1 (fr) 2006-08-19 2008-02-28 Boehringer Ingelheim International Gmbh Arylsulfonamides à effet analgésique
EP2025673A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
EP2025668A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
EP2025675A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
WO2009021945A1 (fr) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Arylsulfonamides à effet analgésique
WO2009021758A1 (fr) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Arylsulfonamides ayant un effet analgésique
WO2009021944A1 (fr) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Nouveaux composés
JP2010504930A (ja) * 2006-09-29 2010-02-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスルホンアミド誘導体
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US8093249B2 (en) 2008-07-17 2012-01-10 Convergence Pharmaceuticals Limited Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US8288388B2 (en) 2008-07-17 2012-10-16 Convergence Pharmaceuticals Limited 3-pyridylcarbonyl-piperazinylsulfonyl derivatives
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US12312352B2 (en) 2012-05-14 2025-05-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in SIRS and/or sepsis

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200817319A (en) * 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
CA2712582A1 (fr) * 2008-02-06 2009-08-13 Norbert Hauel Arylsulfonamides a efficacite antalgique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106428A1 (fr) 2002-06-14 2003-12-24 Laboratoires Fournier Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
WO2004054584A1 (fr) 2002-12-13 2004-07-01 Merck & Co., Inc. Nouveaux derives de quinoxalinone constituant des antagonistes b1 de la bradykinine
WO2004083173A2 (fr) 2003-03-18 2004-09-30 Merck & Co., Inc. Derives de ketopiperazines en tant qu'antagonistes de bradykinine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
US7105172B1 (en) * 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
US7056937B2 (en) * 2002-05-03 2006-06-06 Elan Pharmaceuticals, Inc. Sulfonylquinoxalone derivatives as bradykinin antagonists
EP1741444A1 (fr) * 2005-07-05 2007-01-10 Jerini AG Antagonistes de kinine pour traiter le dysfonctionnement de la vessie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106428A1 (fr) 2002-06-14 2003-12-24 Laboratoires Fournier Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
WO2004054584A1 (fr) 2002-12-13 2004-07-01 Merck & Co., Inc. Nouveaux derives de quinoxalinone constituant des antagonistes b1 de la bradykinine
WO2004083173A2 (fr) 2003-03-18 2004-09-30 Merck & Co., Inc. Derives de ketopiperazines en tant qu'antagonistes de bradykinine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SU, DAI-SHI ET AL., J. AM. CHEM. SOC., vol. 125, no. 25, 2003, pages 7516 - 7517
SU, DAI-SHI ET AL: "Discovery of a Potent, Non-peptide Bradykinin B1 Receptor Antagonist", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 125(25), 7516-7517 CODEN: JACSAT; ISSN: 0002-7863, 2003, XP002375613 *

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8178541B2 (en) 2002-08-21 2012-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US8541450B2 (en) 2004-11-05 2013-09-24 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US12178819B2 (en) 2006-05-04 2024-12-31 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US12171767B2 (en) 2006-05-04 2024-12-24 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
JP2012149086A (ja) * 2006-08-19 2012-08-09 Boehringer Ingelheim Internatl Gmbh 新規化合物
US7858618B2 (en) 2006-08-19 2010-12-28 Boehringer Ingelheim International Gmbh Compounds
EP2284166A1 (fr) * 2006-08-19 2011-02-16 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
WO2008022945A1 (fr) 2006-08-19 2008-02-28 Boehringer Ingelheim International Gmbh Arylsulfonamides à effet analgésique
US8252785B2 (en) 2006-08-19 2012-08-28 Boehringer Ingelheim International Gmbh Aryl sulfonamides as bradykinin-B1-receptor antagonists
JP2010504930A (ja) * 2006-09-29 2010-02-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスルホンアミド誘導体
US8394805B2 (en) 2007-08-14 2013-03-12 Boehringer Ingelheim International Gmbh Compounds
WO2009021758A1 (fr) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Arylsulfonamides ayant un effet analgésique
US8450306B2 (en) 2007-08-14 2013-05-28 Boehringer Ingelheim International Gmbh Bradykinin B1-receptor antagonists
EP2025673A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
EP2025668A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
EP2025675A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
WO2009021945A1 (fr) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Arylsulfonamides à effet analgésique
JP2010535839A (ja) * 2007-08-14 2010-11-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
WO2009021944A1 (fr) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Nouveaux composés
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US8536183B2 (en) 2008-07-17 2013-09-17 Convergence Pharmaceuticals Limited 3-pyridylcarbonyl-piperazinylsulfonyl derivatives
US8093249B2 (en) 2008-07-17 2012-01-10 Convergence Pharmaceuticals Limited Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives
US8288388B2 (en) 2008-07-17 2012-10-16 Convergence Pharmaceuticals Limited 3-pyridylcarbonyl-piperazinylsulfonyl derivatives
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US12312352B2 (en) 2012-05-14 2025-05-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in SIRS and/or sepsis
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US12364700B2 (en) 2016-06-10 2025-07-22 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Also Published As

Publication number Publication date
US20060100219A1 (en) 2006-05-11
EP1812405A1 (fr) 2007-08-01
CA2585535A1 (fr) 2006-05-11
US7291642B2 (en) 2007-11-06
JP2008518889A (ja) 2008-06-05
DE102005013967A1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
EP1812405A1 (fr) Nouveaux antagonistes de la bradykinine b1, procedes de production et d'utilisation en tant que medicaments associes,
DE69830403T2 (de) Inhibitoren des faktors xa mit einer neutralen gruppe mit p1-spezifität
DE60319714T2 (de) Agonisten des cannabinoidrezeptors
AU597696B2 (en) Benzimidazole derivatives
DE60209736T2 (de) Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
DE602004010829T2 (de) Adamantan- und azabicyclooctan- und -nonanderivate, verfahren zu deren herstellung und deren verwendung als dpp-iv-inhibitoren
EP2734517B1 (fr) Benzamides
DE602004012418T2 (de) Piperazinderivate und anwendungsverfahren
EP1437344A1 (fr) Derives de benzene et procede de preparation et d'utilisation associe
CA2759126A1 (fr) Composes comme antagononistes de bradykinine b1
DE19955794A1 (de) Pyrrolidin-Derivate-CCR-3-Rezeptor-Antagonisten
WO2012022487A1 (fr) Dérivés de carboxamide et d'urée cycliques substitués en tant que ligands du récepteur vanilloïde
SK13832002A3 (sk) Pyrolidínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
WO2005105759A1 (fr) Composes de 5, 6, 7, 8-tetrahydro-pyrido[4, 3-d]pyrimidine-2-yl et de 5, 6, 7, 8-tetrahydro-quinazoline-2-yl substituees
ZA200602442B (en) Pyridine derivatives and use thereof as urotensin II antagonists
CN115210233B (zh) 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物
DE60203818T2 (de) Benzotriazepine als gastrin und cholecystokinin rezeptor liganden
JP2011507883A (ja) Ｋｖ１．５カリウムチャネル阻害剤としての４−イミダゾリジノン
JP2006117568A (ja) チオフェン環を有する新規アミド誘導体及びその医薬としての用途
TW202233620A (zh) Cftr調節劑化合物、組合物及其用途
DE10132686A1 (de) Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE69907683T2 (de) Zimtsäure-derivate als zelladhäsions-moleküle
DE60124397T2 (de) Inhibitoren von serinproteasen
EP3130589A1 (fr) Composés aza hétérocyclique
EP1220845B1 (fr) Derives de benzimidazole portant comme substituant un arylsulfonamide et leur utilisation comme inhibiteurs de la tryptase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005800514

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2585535

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007538344

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005800514

Country of ref document: EP